US 11,655,507 B2
Method for diagnosing Parkinson's disease using nasal mucus, composition therefore, and kit comprising the same
Yunjong Lee, Cheongju-si (KR); Hyojung Kim, Daegu (KR); Seok-Hyun Cho, Seoul (KR); Seok-Jae Kang, Gwacheon-si (KR); and Hee-Tae Kim, Seoul (KR)
Assigned to Research & Business Foundation Sungkyunkwan University, Suwon-si (KR); and IUCF-HYU (Industry-University Cooperation Foundation Hanyang University), Seoul (KR)
Filed by Research & Business Foundation Sungkyunkwan University, Suwon-si (KR); and IUCF-HYU (Industry-University Cooperation Foundation Hanyang University), Seoul (KR)
Filed on Sep. 12, 2019, as Appl. No. 16/568,743.
Prior Publication US 2021/0079469 A1, Mar. 18, 2021
Int. Cl. C12Q 1/6883 (2018.01); C12Q 1/6851 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/6851 (2013.01); C12Q 2545/101 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/166 (2013.01)] 12 Claims
 
7. A method for diagnosing Parkinson's disease, the method comprising:
measuring an expression level of parkin gene and an expression level of AIMP2 gene in a nasal mucus sample of a patient,
wherein the measuring of the expression levels comprises detecting a gene transcript, and the expression levels are measured by using one or more oligonucleotide comprising the nucleotide sequence of at least one of SEQ ID No. 5, 6, 7 or 8; and
determining whether said patient has Parkinson's disease based on the measured expression level of parkin gene and the measured expression level of AIMP2 gene.